Given the prevalence of elevated Lp(a) in patients with existing ASCVD (10–15% of such patients would have Lp(a) levels high enough to be eligible for the cardiovascular outcomes trials), these agents could have a major impact on residual risk of ASCVD events in secondary prevention. Here, LPA is linked to atherosclerosis.